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RNA interference (RNAi) is a powerful tool widely used for studying gene function in a number of species. We have 
previously developed an approach that allows conditional expression of a polymerase III promoter based small hairpin 
RNA (shRNA) in mice using the Cre-LoxP system. This approach uses a U6 promoter, which is inactive due to the 
presence of a ploxPneo cassette in the promoter; this promoter can be activated after excision of the neo gene in transgenic 
mice that express a Cre recombinase transgene. As a proof of principle, we have previously knocked down over 95% of 
Fgfr2 transcripts in mouse germlines, leading to embryonic lethality, while restricting the knockdown to the progress zone 
of the limb results in live animals with malformation of digits of both the forelimbs and hindlimbs. We now provide a 
detailed protocol, including a simplified single-step cloning procedure for vector construction. This method provides a fast 
yet efficient way to decipher gene functions in vivo in a tissue specific manner. 
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Introduction 
RNA interference (RNAi) is a technique widely 
used to down-regulate the mRNA level of a specific 
gene. Small interfering RNAs (siRNAs) or small 
hairpin RNAs (shRNAs) are composed of a 22 nt-
double strand RNA sequence completely homologous 
to an unique target gene [1-6]. ShRNAs are generally 
produced by RNA polymerase II or III-based vectors 
while siRNA can be obtained from biotechnology 
companies. The siRNA or shRNA-expressing vectors 
are transfected into cell lines with classical 
lipotransfectants. The homology of sequence with a 
specific target gene allows formation of a complex 
comprising one strand of the shRNA or siRNA 
hybridized with the mRNA target and the RISC 
(RNAi-induced silencing complex) proteins in the 
cytoplasm. RISC then degrades the mRNA, which 
cannot be translated. The whole process leads to the 
specific downregulation of the RNA of the 
corresponding gene within 24-72 hours [2, 3, 7-9]. 
Because of the dominant feature of RNAi in causing 
cell lethality, several studies developed inducible 
regulation of RNAi in mammalian cells to achieved a 
controllable gene knockdown using either 
tetracycline, ecdysone, or tamoxifen-inducible 
systems [8, 10-13].  
RNAi based gene knockdown has also been 
successfully used to study gene functions in mouse 
models [8, 14-21]. In some of these studies, shRNA 
constructs were first introduced into mouse 
embryonic stem (ES) cells through random 
integration [15, 22-24] or homologous recombination 
into the Rosa-26 locus [25]. The ES cells with ideal 
levels of gene knockdown were then injected into 
blastocysts to obtain mutant mice, following a 
standard approach for germline transmission used in 
gene targeting. In some other studies, the mutant 
mice were generated through a transgenic approach, 
i.e. injecting shRNA constructs directly into the 
pronucleus of the oocyte [16, 26, 27]. Mutant mice 
carrying modification of many genes, including 
Dnmt1, p53, Fgfr2, RasGAP, and WT1, have been 
generated using these approaches [22-24, 26, 28-30].  
We have recently described a Cre-LoxP 
mediated shRNA approach that specifically knocks 
down the Fgfr2 gene with high efficiency (>90% 
reduction of transcripts) in a tissue specific fashion [6]. 
This approach has several key features that may 
contribute to the high efficiency of temporal and 
spatial control of gene expression. First, the U6 
promoter is used to ensure a ubiquitous and high 
level expression of short transcripts. Secondly, a 
ploxPneo is inserted into the U6 promoter between its 
proximal sequence element (PSE) and distal sequence 
element (DSE). The presence of the neo gene 
completely blocks transcriptional activity of the U6 
promoter, therefore preventing any potentially lethal 
effect of the shRNA construct during the process of 
transgenic mice production. Lastly, our construct was 
introduced through pronuclear injection, making it 
relatively faster to generate mice than using ES cell 
based approaches. 
This approach has several advantages compared 
with other in vivo approaches. First, because the neo 
gene is flanked by loxP sites, it can be deleted by Cre 
recombinase to restore the activity of the U6 promoter. 
Therefore, multiple studies investigating gene 
function in different tissues and different 
developmental stages can be performed after crossing 
the mutant mice with transgenic mice that express 
Cre in different tissues/organs. A recent study Int. J. Biol. Sci. 2007, 3  92
indicates that tissue specific gene knockdown can also 
be achieved by using tissue-specific polymerase-II 
(polII) promoter, which drives expression of a longer 
double strand RNA (dsRNA) expression unit [30]. 
Although effective, this approach is limited to a 
specific tissue and new transgenic mice carrying 
dsRNA driven by different tissue specific polII 
promoters need to be generated for each tissue of 
interest. Second, we chose to use pronuclear injection 
to generate mutant mice instead of using ES cells. 
This avoids the sophisticated ES cell manipulation 
that is required for germline transmission after the 
blastocyst injection. Thus, our approach should be 
technically easy and reliable. Finally, our approach 
does not require the construction of sophisticated 
gene-targeting vectors. Indeed, cloning the RNAi 
oligos into the shRNA expression vector has been 
simplified into a single step since our initial 
publications [8, 26], making it relatively simple and 
fast to generate mutant mice carrying an shRNA 
construct.  
In this article, we present a detailed protocol to 
generate a U6-based shRNA construct and transgenic 
mice in order to share our approach with interested 
readers for their gene knockdown studies.  
Figure 1. Maps of the two vectors used in the study. (A) pBS/U6-LoxP (active). (B) pBS/U6-ploxPneo (inactive, due to 
the presence of a ploxPneo gene that can be deleted by Cre recombination). The ploxPneo (1936 bp) is derived from the 
PGKneo [38] after adding loxP sites on both end of the PGK neo. Multiple cloning sites and their locations are indicated. 
 
Materials 
Reagents 
DNA oligonucleotides 
Distilled sterilized water (dH2O) 
TE buffer (10 mM Tris-Cl/1 mM EDTA, pH 7.4)  
Low-TE buffer (1 mM Tris-Cl/0.1 mM EDTA, 
pH 7.4) 
ApaI, EcoRI, SalI, Not I, Asp 718, Afl III 
restriction enzymes (Roche) 
DNA polymerase I, large fragment (Klenow) 
(New England Biolabs) 
T4 DNA polymerase (New England Biolabs) 
MinElute Reaction Cleanup kit (Qiagen) 
Qiaprep Spin Miniprep kit (Qiagen) 
Dneasy kit (Qiagen) 
LB media (Add the following to 800 ml H2O (10 
g Bacto-tryptone, 5 g yeast extract, 10 g NaCl). Adjust 
pH to 7.5 with NaOH. Adjust volume to 1L with 
dH2O. Sterilize by autoclaving) 
LB plates 
(http://www.bbri.org/faculty/smith/LB_Plates.html) 
Ampicillin Stock (100 mg.ml-1) (3 g ampicillin 
sodium salt (Fisher BP1760-25), add sterile water to 
raise volume to 30 ml. Filter sterilize through 0.22 µm 
syringe filter. Aliquot into 1 ml and store at –20°C). 
Competent cells (DH5α, Invitrogen)  
UltraTMPhenol: Chloroform: Isoamyl Alcohol 
(Invitrogen, Cat No. 15593-031). 
(Caution: these are chemical reagents with 
harmful effect) 
RNA-Stat-60 reagent 
Agarose powder (Gibco BRL, Invitrogen) 
Ethidium bromide 
QIAquick gel extraction kit 
Nylon membrane (PROTRAN Plus from 
Scleicher & Schuell) 
Sheets of 3M Whatman Chromatography filter 
paper and saran wrap 
15% (wt/vol) polyacrylamide-8 M urea gel 
Loading dye (contains 0.025 % Bromophenol 
blue, 0.025% Xylene Cyanol, 0.5 mM EDTA, 0.025% 
SDS) 
10X TBE (Quality Biological, Inc.; Cat # 330-001-
161) 
PERFECTHYBTMPLUS (Sigma, Product no. H Int. J. Biol. Sci. 2007, 3  93
7033) 
10X PNK buffer (Roche 1465492) 
γ32P ATP (Amersham AA0068 250 μCi). 
CAUTION: radioactive material. Manipulate under 
appropriate conditions 
Poly Nucleotide Kinase (PNK) (10u/μl, Roche 
709557)  
G25 column (Amersham 27- 5325-01)  
Column 4K (X100) 
20X SSPE (Quality Biological, Inc.; Cat # 330-015-
161)  
20X SSC (Quality Biological, Inc.; Cat # 330-003-
161)  
20% SDS (Quality Biological, Inc.; Cat # 351-066-
101) 
dNTP: DNA polymerization mix is available at 
20mM/dNTP commercially; take 2 µl of 
20mM/dNTP mix and make up the volume 100 µl 
with dH2O. It will give 400 µM/dNTP solution. 
CRITICAL: keep on ice during all the preparation of 
the reactions 
Loading buffer: 12% FICOLL 400 by weight or 
12 % glycerol by volume ; 60 mM Na2EDTA, pH 8 ; 
0.6% by weight SDS ; 0.003% by weight bromphenol 
b l u e   ;  0 . 0 0 3 %  b y  w e i g h t  x y l e n e  c y a n o l  ( f o r  h i g h  
molecular weight bands) 
TAE 10X concentrated aqueous solution: Tris-
Hcl 48.46 g/L (0,4 M), EDTA-Na,-salt 3.72 g/L (0.01 
M), Acetic acid 12.01 g/L (0.2 M) 
pBS/U6-loxP and pBS/U6-ploxPneo vectors (Fig. 
1): The generation of these vectors from the original 
U6 promoter [31] was as described [8]. Both vectors 
are available upon request. 
Lipofectamine (2000) (Invitrogen) 
Cells –to-cDNATM II kit (Ambion, Cat # 
1722,1723) 
Equipment  
Computer with internet access 
Eppendorf tubes 
Eppendorf Centrifuge (5415 D) 
Heater 
Floater 
Beaker 
Spectrophotometer (cuves) 
Water bath 
Shaker for bacteria suspensions 
Bacteria plates incubator 
Sterilized materials (toothpicks) for 
transformation procedure 
Ultraviolet transilluminator 
Gene Amp PCR Systems 9700 
Taqman PCR (Gene Choice) 
Stratagene UV Crosslinker 
Baker 
Geiger counter 
Cassette and phosphorimager screen 
XCell IITM Blot Module 
Hybridization oven 
Poly Acrylamide Gel Electrophoresis (PAGE) 
apparatus 
Animals 
F V B / n  m i c e  ( J a c k s o n  l a b )  w e r e  u s e d  f o r  
generating transgenic mice. 
Reagent setup  
1. Designing oligos  
With an internet browser, connect to 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi. Select in 
the Search tool bar « Nucleotide » and search for your 
mRNA or cDNA of interest throughout the Accession 
Number or name. Within the nucleotide sequence, 
select a region starting with one or two G (G or GG), 
followed by 19-20 bases to obtain a total of 20-21 
nucleotides (nt) sequence and check that this whole 
sequence is 45-65% G/C. Finally, use a BLAST2 
program (http://www.ebi.ac.uk/blast2/ for example) to 
check that the sequence is unique and has no 
significant homology with any other known ones. 
Additional information regarding nucleotides 
selection can be found in a recent publication [32].  
Oligo 1: the native U6 promoter contains a 
(GGG), from which transcription is initiated. This 
motif is part of an ApaI restriction site (GGGCC/C). 
In the procedure, the ApaI site is cut and blunted, 
leaving only one G left at its 3’ end. The first strand of 
oligo 1 then contains one or two G at the 5’ end which 
will be cloned at the ApaI site. An example of oligo 1 
for Fgfr2 gene is shown in Fig. 2A. In this oligo, we 
added a HindIII site (AAGCTT), which serves as a 6-
base loop of the hairpin, in the oligo following the 
first 20-21 bp. The last part of the oligo is the 
complementary sequence of the 20-21 bp followed by 
three “C” corresponding to the complementary 
sequence of the first three “G”, five “T” 
corresponding to the termination site of the RNA 
polymerase III, and then one G, which will form an 
EcoRI site after annealing with oligo 2.  
Oligo 2 must be complementary to the Oligo 1 
except for 4 nt (AATT) that are added to the former’s 
5’ end (Fig. 2B). This nt forms a digested EcoRI site 
(Fig. 2C), which will be used for cloning purposes. 
After transcription by U6 promoter, a hairpin 
structure will be formed in which the HindIII 
sequence form the head of the hairpin structure (Fig. 
2D). 
Note 1: We normally start with at least three 
candidate regions for the first oligo design so that the 
best sequence can be determined. Ensure that the 
designed oligos do not contain a (TTTTT) and a 
(AAAAA) motifs inside the 20-21 sequence. To avoid 
multiple inserts, do not order phosphorylated oligos. 
We ordered oligos from Operon Biotechnologies, 
although the source may not be critical. 
Note 2: A recent study compared hairpin loops 
formed by several different sequences in cell culture 
condition. It was shown that the loop formed by 
“UUCAAGAGA” seems to have a higher efficiency than 
loops formed by other sequences [33], although its 
efficiency in vivo remains elusive. In this case, the 
nucleotide “TTCAAGAGA” can be used instead of 
“AAGCTT”. Int. J. Biol. Sci. 2007, 3  94
Figure 2. An example of used oligos for shRNA vector. (A) Oligo 1 contains a two complementary sequences (in black) 
that can be formed upon shRNA transcription, a hairpin structure. A Hind III site forms the hairpin structure (see figure 2D 
in red). (B) Oligo 2 is complementary of oligo 1. Both oligos are designed against mouse Fgfr2. (C) Annealed Oligos 1 
and 2. (D) Predicted hairpin structure with the corresponding colors (black: target sequence; red: Hind III site for hairpin). 
 
 
Procedure  
2. Annealing oligos 
a. Prepare a 0.2 μg/μl stock solution of each 
Oligo (1 and 2, see Reagent Setup) with TE buffer. 
b. Mix the components in an Eppendorf tube as 
shown in Table 1. 
Table 1. Annealing oligos. 
Component Amount  Final 
Ligation buffer (10X)  4 μl 1X 
Oligo 1 (0.2 μg/μl) 18  μl 0.09  μg/μl  
Oligo 2 (0.2 μg/μl) 18 μl 0.09  μg/μl 
TOTAL 40  μl  
 
c. Heat 1 L of water in a beaker on a heater until 
the water reaches 70°C. 
d. Place the tube on a floater into the beaker and 
keep the tube at 70°C for 5 minutes. 
e. Move the whole beaker onto the bench and let 
it cool down for 1 hour or until the water reaches 
room temperature.  
Subcloning the double-stranded oligo into the 
vector. 
3. ApaI restriction of the vector.  
Mix the components in an eppendorf tube as 
shown in Table 2. 
Table 2. ApaI restriction digestion of U6 vector. 
Component Amount  Final 
pBS/U6-Neo vector  5 μg  
Buffer A (10X)  2.5 μl 1X   
ApaI   1 μl 2  unit/μg of the 
vector 
TOTAL (make up 
with dH2O 
25 μl  
 
Incubate at 30°C for 2 hours. 
Check the digestion of the vector by running 1 μl 
of the digestion mixture on 1% agarose gel.  
Make sure the pBS/U6-Neo vector DNA is 
produced in a dam– b a c t e r i a  s t r a i n  t o  a v o i d  
methylation of the vector (ApaI is methylation-
sensitive). 
4. Blunt the ApaI-digested DNA with T4 DNA 
polymerase or Klenow enzyme (which works with 
lower efficiency than T4 DNA polymerase).  
The DNA was then Phenol-Chloroform 
extracted and resuspend in 10 µl of Low-TE. Measure 
the DNA concentration. It should contain more than 
2.5μg of DNA. 
5. EcoRI restriction.  
Add the reagents to an Eppendorf tube as 
shown in Table 3. 
Table 3. EcoRI restriction digestion of the vector.  
Component Amount  Final 
ApaI digested and 
blunted pBS/U6-neo 
vector 
2.5μg    
Buffer H (10X)  2.5 μl  1 X  
EcoRI   1 μl (10 unit)  4 unit/μg of the 
vector 
TOTAL (make up 
with dH2O 
25 μl  
 
Incubate at 37°C for 2 hours. 
Purify the vector by Phenol-Chloroform 
extraction. 
Resuspend the DNA in 20 μl of TE. Measure 
DNA concentration. 
6. Ligation of oligos-1/2 into the pBS/U6-Neo 
ApaI+EcoRI- digested vector.  
a. Mix the components in an Eppendorf tube as 
shown in Table 4. Int. J. Biol. Sci. 2007, 3  95
Table 4. Ligation of oligos-1/2 into ApaI+EcoRI- digested 
U6 vector. 
Component Amount  Final 
ApaI+EcoRI- 
digested pBS-U6-
Neo vector  
100 ng   
Annealed oligos  0.25 μl  
Ligation buffer (10X)  2 μl 1X 
T4 DNA ligase  2 μl 1-2  unit/reaction 
dH2O 14  μl  
TOTAL   20 μl  
 
b. Centrifuge 10 seconds and incubate overnight 
at 16°C.  
7. Transformation 
a. Thaw competent cells (100 µl) on ice. 
b. Add 5 to 10µl of the ligation mixture and mix 
gently by pipetting. 
c. Incubate on ice for 30 minutes. 
d. Heat shock for 45 seconds at 42°C and chill on 
ice for 5 minutes. 
e. Add 0.9 ml of room temperature LB media 
and incubate at 37°C for 1 hour in a shaker (225 rpm). 
f. Spread 100 to 300 µl of the solution on LB 
plates containing ampicillin. 
g. Incubate overnight at 37°C. 
8. Screen for colonies containing insert.  
a. Pick 18 colonies from the LB plates with 
sterilized toothpicks and culture each colony in 2 mL 
of fresh LB media supplemented with ampicillin (100 
µg.ml-1) for overnight. 
b. Using QIAprep Spin Miniprep Kit, or regular 
method for miniprep to purify the corresponding 
pBS/U6-Neo-shRNA vectors and dissolved in 20 μl of 
TE. 
c. Perform the restriction as shown in Table 5. 
Table 5. Digestion of DNA using EcoRI + SalI. 
Component Amount  Final 
DNA from miniprep  2.0 μl    
EcoRI 1  μl 10  unit/reaction 
SalI 1 μl 10  unit/reaction 
Buffer H  2.5 μl (10X)  1X 
TOTAL   25 μl  
 
A master mix can be made for 20 samples 
(without DNA), and 23 μl aliquots should be divided 
into 19 Eppendorf tubes. Add 2 μl of DNA extracted 
from each colony (a total of 18 colonies) into each 
Eppendorf tube. Also add 100 ng of parent pBS-U6-
Neo DNA into the 19th tube, which will be used as a 
control without insert. 
d. Incubate at 37°C for 2 hours. Run the samples 
on a 3% agarose gel. The parent pBS-U6-Neo vector 
will release a 124 nt fragment, while the DNA with 
one insert will release a 141 nt fragment. The 
difference of 17 nt is visible in the 3% agarose gel 
(Figure 3 A).  
Figure 3. Screening for the U6-Neo-RNAi vector containing the insert and its expression in mouse after deletion of the 
neo by EIIa-Cre transgene. (A) After double-strand oligo ligation into the pBS/U6-neo vector, check insertion by SalI and 
EcoRI restriction and migration in a 3% agarose gel. Run two controls (parent and restricted parent vector) and an 
appropriate molecular weight marker (100, 150 and/or 200 bp). (B) Northern blot showing expression of pBSU6-Neo-
RNAi against mouse Fgfr2. Cre mediated deletion of the neo from U6-ploxPneo-Fgfr2 transgene allows expression of 
Fgfr2 RNAi. (C) Assessment of copy number of U6-ploxPneo-Fgfr2 transgene by realtime PCR using primers for neo 
gene. Control DNA with 1 copy and 2 copies of neo gene are from Sirt6+/- and Fgfr1-/- ES cells, respectively. (D) RT-
PCR analysis of Fgfr1-4 expression in E12.5 embryos of different genotypes. Wt: Wild type; U6: U6-ploxPneo-Fgfr2; Cre: 
EIIa-Cre; and U6;Cre: U6-Fgfr2;EIIa-Cre. The first row is a longer exposure of the second row. Three embryos for each 
genotype were shown. RT-PCR was performed using the following primers: Fgfr1-F: 5’-
TTCTGGGCTGTGCTGGTCAC-3’, and Fgfr1-R: 5’-GCGAACCTTGTAGCCTCCAA-3’. Fgfr2-F: 5’-
AAGGTTTACAGCGATGCCCA-3’, and Fgfr2-R: 5’-ACCACCATGCAGGCGATTAA-3’. Fgfr3-F: 5’-
CTAGTGTTCTGCGTGGCGGT-3’, and Fgfr3-R: 5’-TTCTTATCCATTCGCTCCGG-3’. Fgfr4-F: 5’-
CTGTTGAGCATCTTTCAGGG-3’, and Fgfr4-R: 5’-CGTGGAAGGCCTGTCCATCC-3’.  
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Critical step  
1). The insert is 53 nt. Because ApaI+EcoRI 
digestion cuts away 36 nt from the parent vector, the 
net gain with one insert is 17 nt. 
2). In our original study by Coumoul et al. 
(2004)[8], we used two consecutive steps to clone a 
total of 4 shorter oligos (oligos 1-4) into the shRNA 
vector in order to avoid formation of hairpins of the 
oligos. We now found this is not necessary and only 
use a one-step protocol to introduce 2 longer oligos 
(oligos 1 and 2). If you encounter any trouble in using 
this one-step oligo cloning, a two-step cloning 
procedure can be used [8, 31].  
9. Sequencing the clones  
Once DNA vectors containing a single insert is 
c o n f i r m e d ,  w e  s e n d  t h e m  t o  G E N E W I Z ,  I N C  f o r  
sequencing using two primers. One primer (5’– 
GCTATGACCATGATTACGCCA – 3’) is located at 
3017-3040, which is 131 bp away from ApaI (located 
at 2886). Another primer (T3 primer: 5' - 
ATTAACCCTCACTAAAGGGA - 3’) is located at 
2992-3011, which is 106 bp away from ApaI. Both 
primers yield good sequencing.  
10. Checking the efficiency of the shRNA vector  
Because the presence of the ploxPneo cassette 
completely blocks the activity of the U6 promoter, it 
must be deleted by the Cre-loxP mediated 
recombination in cultured cells using one of the 
following procedures.  
Option A describes a transient transfection 
procedure to delete the neo and should be used by 
researchers who consider a fast evaluation of gene 
knockdown. Option B describes a stable transfection 
and should be used when the fast evaluation 
procedure does not yield a clear result. Option C 
describes a convenient system to get shRNA vector 
and should be used by the labs, who do not have Cre 
recombinase system available. In all three procedures, 
the test should be performed in cells that express the 
target gene. Alternatively, a plasmid expressing the 
target gene needs to be co-transfected with shRNA 
expressing constructs. 
Option A: 
1) The U6-Neo-RNAi construct can be 
transfected into cultured cells bearing constitutively 
expressed Cre or inducible Cre using lipofectamine 
2000 following a recommended procedure 
(http://www.invitrogen.com/content/sfs/manuals/
lipofectamine2000_man.pdf) .  P a r e n t  U 6 - N e o  v e c t o r  
without insert can be used as control.  
2) After 48-72 hours of transfection, cells will be 
harvested and total RNA will be prepared using RNA 
STAT-60 (Tel-Test, Inc., Friendswood, TX) for RT-
PCR (Cells-to-cDNA TM II protocol for reverse 
t r a n s c r i p t i o n )  a n a l y s i s  o f  t a r g e t  g e n e  e x p r e s s i o n .  
RNAi knockdown is considered successful if about 
70% of the mRNA target is degraded.  
Option B:  
1) The U6-Neo-RNAi construct can be 
transfected into regular cells followed by G418 
selection.  
2) Cells with a stable integrated U6-Neo-RNAi 
construct are then be transfected by Cre-expressing 
vector to delete the neo gene.  
3) Alternatively, cells with inducible Cre can also 
be used for transfection. Cells with a stable integrated 
U6-Neo-RNAi construct are then placed in a Cre 
induction condition to delete the neo gene followed 
by RT-PCR analysis of target gene expression.  
Option C: 
For those laboratories where a Cre expression 
vector is not available, the shRNA vector can be 
generated in parallel by cloning the annealed oligo 
1/2 (Step 2) into U6-RNAi vector (Fig. 1A). Because 
this vector does not contain the ploxPneo, the U6 
promoter should be active when directly transfected 
into regular cells. 
All above procedures work efficiently in our 
laboratory [8] and in the literature for assessing 
knockdown efficiency of vector based siRNAi 
expression. 
Generation of transgenic mice 
11. Preparing vectors for pronuclear injection. 
  The pBS/U6-Neo-shRNA vector is digested 
with Asp718 and AflIII according to the restriction 
procedure  used in the previous paragraphs (see 
paragraph 4 and 6). After gel electrophoresis, we 
purify a 2739 bp fragment using the QIAquick Gel 
Extraction Kit (Qiagen, Valencia, CA). The fragment 
is resuspended in Low-TE buffer and adjusted to a 
final concentration of 2ng/μl and injected into 
oocytes isolated from FVB/N mice through 
pronuclear injection. All animals are maintained and 
treated according to the approved NIH guidelines 
and techniques 
(http://www.nih.gov/science/models/mouse/sharing/5.html).  
12. Identifying G0 transgenic founder mice and 
screening for germline transmission.  
a. Cut off 0.5 cm of the tails from weaned pups 
born to mothers carrying injected blastocysts and 
carry the tails in Eppendorf tubes. Isolate genomic 
DNA using Qiagen’s Dneasy kit and proceed to 
genotyping according using PCR with the following 
pair of primers (5’-CGAAGTTATCTAGAGTCGAC-3’, 
and 5’-AAACAAGGCTTTTCTCCAAGG-3’) that 
amplifies 102 bp from the U6 promoter and the 
connecting neo gene.  
b. Amplify the template as shown in Table 6. 
Table 6. PCR conditions for detecting the U6-neo 
transgene.  
Cycle 
number 
Denaturation Annealing  Polymerization 
1  2 minutes at 
94°C  
  
2-34  10 seconds at 
94°C 
20 seconds at 
60°C 
30 seconds at 
72°C 
35   10 seconds at 
94°C 
20 seconds at 
60°C 
10 minutes at 
72°C 
 
c. Run the PCR product in a 2.5% agarose gel to 
identify the positive G0 transgenic founder mice.  
The PCR positive mice are candidate that carry 
the U6-Neo-RNAi transgene. These mice are crossed 
with wild type FVB/N mice to obtain germline 
transmission. The offspring mice containing the 
transgene are the F1 generation. Int. J. Biol. Sci. 2007, 3  97
13. Generate U6-ploxPneo-RNAi/Cre mice.  
Because the presence of the ploxPneo in the 
RNAi vector that inactivate the U6 promoter activity, 
the F1 mice should be normal. To study the effect of 
RNAi mediated knockdown, the ploxPneo gene 
should be deleted. To achieve this, two independent 
strains of F1 mice carrying the U6-ploxPneo-RNAi 
transgene are crossed with mice carrying 
ubiquitously or tissue specifically expressed Cre 
transgene to create bigenic mice (U6-Neo-RNAi/Cre) 
that can be used for phenotypic analysis.  
 
14. Monitoring Cre-mediated recombination.  
The product generated by Cre-loxP mediated 
recombination in the U6-ploxPneo-RNAi/Cre bigenic 
mice can be visualized by using a primer pairs 
flanking the ploxPneo: 1: 5’-
CGCACAGACTTGTGGGAGAA-3’; and 2: 5’-
CACAATTACTTTACAGTTAG-3’. 1 μg of DNA 
extracted from various tissues of bigenic mice can be 
used in the PCR reaction (as described in step 12).  
 
15. Determining U6-RNAi transgene expression.  
Because the transcript of the U6-RNAi transgene 
is very short, it can only be detected by Northern blot 
protocol that is optimized for short transcripts. A 
clear and sharp band can be obtained after 24-48 hour 
exposure (Fig. 3B). The following detailed northern 
protocol is optimized to detect processed small 
transcripts [26]. 
a. Mix 20 μg RNA (volume of 15 μl) with 12 μl of 
loading dye (contains 0.025% Bromophenol blue, 
0.025% Xylene Cyanol, o.5 mM EDTA, 0.025% SDS). 
Heat samples in 90°C heat block for 5 minutes and 
then place it on ice. Load the samples onto 15% 
(wt/vol) polyacrylamide-8 M urea gel.  
b . Run  ge l i n  1X  T BE r u n n in g b u ffe r  at  2 0 0 V 
approximately 2-3 hrs or until bromophenol blue dye 
migrates above bottom of the gel.  
c. Stain the gel with 4 μg/ml EtBr in 0.5X TBE for 
5 min, and look for tRNA and 5S rRNA bands for 
quality of RNA prep and for loading control. Take 
digital snapshots of the gel and save images. 
d. Set up transfer using XCell IITM Blot Module, 
(Invitrogen Cat No # EI9051). Cut Nylon Membrane 
(PROTRAN Plus from Scleicher & Schuell) and 8 
sheets of 3M Whatman Chromatography filter paper 
to the size of the gel. Presoak membrane and filter 
paper in 0.5X TBE. It is important that both are 
thoroughly soaked. Place 4 pieces of soaked filter 
paper on top and 4 on the bottom, with the 
membrane underneath the gel. Transfer at constant 
current (12V) for 1-2 hours in 0.5X TBE.  
e. While the blot is still moist (leave it on the wet 
3MM support), UV crosslink with 1000 mJ of energy 
(Stratagene UV Crosslinker) RNA side up towards 
the lamps.  
Pause point: Membrane can be wrapped and 
kept at room temperature for 2-3 days. 
f. Prehybridize the membrane with 
PERFECTHYBTMPLUS (Sigma, Product no. H7033) in 
a hybridization oven and rotate at 42°C for 2-4 hours. 
g. Labeling probe as shown in Table 7.  
Table 7. Label Oligo 1 with γ 32P ATP. 
Component Amount Final 
Oligo 1  0.6-1 μl 50-100  ng 
Polynucleotide kinase 
buffer (10X) 
2 μl 1X   
γ 32P ATP  6 μl 50-60  μ Curie 
Polynucleotide kinase   1 μl 10  units 
TOTAL 20  μl  
 
Incubate 30 minutes at 37°C and put on ice. 
Pass through G25 column (Amersham 27- 5325-
01) and check labeling efficiency (Column 4K (X100); 
Probe more than 5K (X100). 
h. Hybridize the membrane at 42°C overnight 
with labeled probe in fresh hybridization buffer. 
CRITICAL: Hybridization solution was used 
according to oligo size. For oligo less than 25 mer, 6X 
SSPE is used, while oligo longer than 25 mer, 5X SSPE 
should be used. Hybridization solution is comprised 
of SSPE (5X or 6X), 5X Denharts, 0.5% SDS and carrier 
DNA 250-300 μl (from 10 mg/ml) for 50 ml.  
i. After the hybridization the membrane was 
washed with 6X SSPE, 0.1% SDS (add 300 ml of 20X 
SSPE and 5 ml of 20% SDS into 695 ml of dH2O) at 
42°C for 10 minutes, and then washed with 2X SSC, 
0.1% SDS (add 100 ml of 20X SSC and 5 ml of 20% 
SDS into 895 ml of dH2O) two times at 42°C for 10 
minutes.  
j. Drain and wrap in Saran Wrap and expose to 
X-ray film keeping the blot moist if it is not washed 
enough and need to be rewashed. 
16. Determine the copy number of the transgene 
Assessment of copy number of U6-ploxPneo-
Fgfr2 transgene by real-time PCR using primers (Neo-
U: 5’-AGAGGCTATTCGGCTATGACTG-3’, and Neo-
D: 5’-GTGGCCAGCCACGATAGC-3’) for neo gene. 
We used DNA extracted from Sirt6+/- and Fgfr1-/- ES 
cells as controls for 1 copy and 2 copies of neo gene, 
respectively. However, DNA extracted from any 
mouse cells carrying one copy and 2 copies of neo 
gene should be fine for this experiment. Relative copy 
of copies of transgene can be calculated against the 
known copy numbers (Fig. 3C). 
17. Determining expression levels of the target gene.  
Expression of the target gene can be evaluated 
by RT-PCR using RNA isolated from organs/tissues 
where Cre is expressed. Western blot analysis 
(Molecular Cloning protocol) can also be used if 
antibody is available. Efficiency of gene knockdown 
can be determined through comparing expression 
levels of the target gene between mutant and control 
mice. An example of Fgfr2 expression in the Fgfr2-
neo-RNAi/EIIa-Cre [34] mice analyzed by RT-PCR 
was shown in figure 3D.  
Sometimes RNAi may generate non-specific 
toxicity due to off-target effects. Much of the off-
target effects can be avoided by conducting a careful 
homology search in designing the first oligo to select 
sequences that are unique in the genome (Step 1). In 
addition, for targeted genes that belong to families 
containing highly related members, gene expression 
study should be performed to detect any possible 
alterations of these members. An example of gene 
expression of other three members of Fgf receptor Int. J. Biol. Sci. 2007, 3  98
family is shown in Fig. 3D. 
Troubleshooting 
As suggested in Table 8. 
Table 8. Troubleshooting. 
Problems Solution 
Step 7, No colony after 
transformation 
The ratio of insert to vector was not 
adequate. In step 3, the ratio of insert to 
vector is 40:1. It can be varied from 10-
100:1.  
Step 8, No visible 
difference of bands 
Always use at least 3% agarose gel and run 
for 2-3 hrs at 180 V. 
Step 9, Sequencing does 
not work 
Sometimes, it is difficult to read through 
the hairpin because of its strong secondary 
structure. We have tried a few companies 
and found Genewiz Inc. can read through 
the hairpin structure with good results.  
Step 10, No decreased 
expression of the target 
gene 
It can be caused by poor transfection 
efficiency. Try to find an adequate 
protocol for transfection. Another 
possibility is that the RNAi oligo does 
not work. If this is the case, new RNAi 
oligo should be used. We normally start 
with oligos against two different 
regions of the target gene and rarely 
found both do not work. 
Timeline  
Step 1-9: Two to four weeks. 
Step 10: Two to four weeks. 
Step 11: One to two months to generate 
transgenic founder mice. 
Step 13-17: After chimera mice are generated, it 
takes about one to two more months to get F1 mice, 
and another two months before knockdown 
phenotypes can be examined from crosses of F1 mice 
with Cre expressing mice. 
Anticipated results  
Under our injection conditions (NIDDK 
Transgenic Core Facility), about 15% of the mice 
should be chimeras carrying the U6-Neo-RNAi 
transgene. After crossing with wild type FVB/N mice, 
more than 50% of the chimeric mice can pass the 
transgene in the first litter. Based on our expression 
studies on at least two strains, we show that 
transgenic mice carrying U6-Neo-Fgfr2RNAi 
constructs are normal, displaying Fgfr2 transcripts 
equivalent to those of wild-type controls (Fig. 3D), 
indicating that the U6 promoter is inactive in vivo 
due to the presence of the neo in the promoter. We 
were unable to detect expression of shRNA in those 
mice (Fig. 3B), suggesting that the presence of the 
ploxPneo gene inactivated the U6 promoter. Similar 
results have been recently shown by other studies [25, 
35], although a neo gene with of smaller size (about 
800 bp) is less tight in silencing U6 promoter activity 
[35] compared with the ∼1900 bp neo cassettes [8, 25, 
26]. After excision of the neo through crossing with 
transgenic mice that express Cre in the mouse 
germline, the U6 promoter is re-activated, leading to 
over 95% reduction of Fgfr2 transcripts (Fig. 3D).  
Like all other transgenic mice generated by 
pronuclear injection, the U6-Neo-shRNA construct 
randomly integrates into mouse genome. The levels 
of shRNA expression are likely to vary among 
transgenic lines due to integration sites and copy 
number. In Step 13, we crossed two independent F1 
mice carrying the U6-ploxPneo-Fgfr2RNAi transgene 
with mice carrying Cre transgene to create bigenic 
mice (U6-Neo-Fgfr2RNAi/Cre) for assessing 
knockdown effects, and found that both strains 
showed similar phenotypes [26]. For those who 
intend to avoid potential expression variation due to 
position/copy number effects, the U6-NeoshRNA 
construct can be targeted into a known open 
chromosome locus with a single copy shown by Yu 
and McMahon (2006) [25]. On the other hand, 
phenotype variation is observed even in mice 
generated by gene targeting, suggesting that it is an 
intrinsic nature associated with the loss of function 
mutation, perhaps due to a different response of each 
individual to the assault. Actually, this could be 
beneficial in some circumstances where variable 
phenotypes may reveal new and unexpected 
information. For example, we and many others have 
purposely used sophisticated targeting modifications 
to generate hypomorphic alleles or isoform knockouts 
[36, 37]. Thus, for those who intend to find strains 
with varying levels of target gene expression so that a 
series of “mutant allele” can be generated for a wild 
range of gene function analysis, more F1 strains need 
to be used in Step 13. 
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